Knights of Columbus Asset Advisors’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.7M Buy
55,259
+8,487
+18% +$1.67M 0.59% 42
2026
Q1
$9.17M Buy
46,772
+693
+2% +$135K 0.52% 47
2025
Q4
$8M Buy
46,079
+1,110
+2% +$202K 0.45% 58
2025
Q3
$8.57M Sell
44,969
-3,951
-8% -$701K 0.49% 56
2025
Q2
$8.79M Buy
48,920
+2,526
+5% +$439K 0.53% 54
2025
Q1
$7.85M Buy
46,394
+1,945
+4% +$320K 0.54% 55
2024
Q4
$6.71M Buy
44,449
+2,697
+6% +$419K 0.44% 66
2024
Q3
$6.48M Sell
41,752
-3,321
-7% -$496K 0.43% 74
2024
Q2
$6.17M Buy
45,073
+496
+1% +$67.9K 0.4% 72
2024
Q1
$5.93M Sell
44,577
-2,222
-5% -$288K 0.43% 63
2023
Q4
$6.45M Buy
46,799
+1,038
+2% +$136K 0.42% 68
2023
Q3
$5.58M Buy
45,761
+647
+1% +$86.2K 0.51% 50
2023
Q2
$6.34M Sell
45,114
-380
-0.8% -$52.4K 0.57% 34
2023
Q1
$6.44M Hold
45,494
0.63% 23
2022
Q4
$7.12M Sell
45,494
-3,890
-8% -$559K 0.74% 22
2022
Q3
$6.06M Sell
49,384
-2,664
-5% -$351K 0.62% 32
2022
Q2
$6.92M Buy
52,048
+473
+0.9% +$64.5K 0.69% 31
2022
Q1
$7.06M Buy
51,575
+1,091
+2% +$152K 0.6% 43
2021
Q4
$8.73M Buy
50,484
+2,003
+4% +$305K 0.71% 24
2021
Q3
$7.04M Buy
48,481
+442
+0.9% +$64.7K 0.63% 33
2021
Q2
$6.34M Buy
48,039
+892
+2% +$117K 0.58% 48
2021
Q1
$6.05M Buy
47,147
+2,266
+5% +$279K 0.59% 38
2020
Q4
$5.35M Sell
44,881
-3,149
-7% -$384K 0.57% 36
2020
Q3
$5.5M Buy
48,030
+3,075
+7% +$363K 0.68% 32
2020
Q2
$5.12M Buy
44,955
+4
+0% +$424 0.63% 33
2020
Q1
$3.61M Buy
44,951
+6,843
+18% +$708K 0.46% 61
2019
Q4
$4.07M Buy
+38,108
New +$3.97M 0.36% 70
2018
Q2
Sell
-6,900
Closed -$719K 90
2018
Q1
$692K Buy
6,900
+1,900
+38% +$195K 0.32% 78
2017
Q4
$492K Hold
5,000
0.32% 80
2017
Q3
$468K Sell
5,000
-100
-2% -$10.6K 0.32% 83
2017
Q2
$567K Sell
5,100
-2,200
-30% -$233K 0.39% 81
2017
Q1
$717K Buy
+7,300
New +$696K 0.51% 77

Other funds holding DGX

Knights of Columbus Asset Advisors's DGX Position: Q2 2026 in Review

Knights of Columbus Asset Advisors increased its Quest Diagnostics (DGX) stake by 18% in Q2 2026, buying an estimated $1.67M and bringing the position to 55,259 shares worth $11.7M. The position accounts for 0.59% of the portfolio, ranked #42.

Knights of Columbus Asset Advisors first reported a position in DGX in Q1 2017 and has held it in 32 quarters since. 629 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Knights of Columbus Asset Advisors held 55,259 shares of Quest Diagnostics worth $11.7M as of Q2 2026.
  • Knights of Columbus Asset Advisors bought 8,487 Quest Diagnostics shares in Q2 2026, an estimated $1.67M.
  • Quest Diagnostics made up 0.59% of Knights of Columbus Asset Advisors's portfolio in Q2 2026, its #42 holding.
  • Knights of Columbus Asset Advisors first reported a position in Quest Diagnostics in Q1 2017 and has held it in 32 quarters since.
  • 629 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Knights of Columbus Asset Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.